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ABSTRACT 
In the current situation in the health care industry is to face many challenges to cure the cancer. The second highest deaths were noticed by the 
cancer in society. Therefore, the efficient treatment is required. There many treatmentsare available to cure the cancer but not found much 
efficient.  The advance development in the hydrophobic drug in the form of water-soluble drug cyclodextrin complex in liposomes has been 
investigated. This new investigation in to the complex in liposomes play key role in combination of the cyclodextrin and liposomes in the one 
common system. Such system would potentially increase the drug to lipid mass ratio. In comparison to conventional treatment this ratio is high 
therefore it enlarges the range of insoluble drug amenable to encapsulation to include, allow targeting, of complexes to specific sites and reduce 
toxicity, for instance and membrane destabilizing agents. This extensive review explores the novel drug delivery for the cancer treatment.  
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1. INTRODUCTION 
Some of the clinically effective drugs are hydrophobic in 
nature. However, to be pharmacologically active all drugs 
must possess some degree of water solubility, especially for 
parenteral administration. Therefore, to improve water 
solubility of drugs different strategies have been proposed. 
Cyclodextrins (CDs), produced from starch by means of 
enzymatic conversion, are one of the most versatile 
strategies in pharmaceutical technology, as an interest of 
formulation for a wide range of drug delivery systems from 
traditional dosage forms to novel drug carriers 1. CDs are 
hydrophilic water-soluble oligosaccharides that contain 
hydrophobic cavities which can accommodate hydrophobic 
drugs. Their outer surface permits aqueous miscibility. The 
number of glucose units determines the name and size of the 
cone linked cavity: α CD, β CD and γ CD, having six, seven and 
eight glucose units respectively. In order to increase their 
aqueous solubility, some chemical modifications have been 
applied to obtain better water-soluble CD derivatives 
including hydroxypropyl β CD (HP β CD), sulfobutylether β 
CD (SBE β CD), methylated β CD (M β CD), and 
hydroxypropyl γ CD (HP γ CD). CDs can also increase the 
stability and even bioavailability of drug molecules by 
inclusion complex formation by a molecular complexation 2, 
3. No covalent bonds are formed during formation of the 
inclusion complex. Therefore, the binding force is relatively 
weak.  
After administration, the rapid dissociation of drug/CD 
inclusion complexes takes place either because of dilution by 
the plasma and extracellular fluids or because blood 
components displace the included drug. Thus, the 
dissociated drug which is separated from its carrier will be 
rapidly cleared at the rate of free drug from blood 
circulation. The CD molecules are mainly excreted through 
the kidney 4, which may induce renal toxicity especially after 
chronic use 5, 6. Another hard obstacle in the use of CDs is 
that some kinds of CDs, especially M β CD, can interact with 
the membrane components of living cells causing 
irreversible changes in physical stability. CDs can remove the 
components of human erythrocyte membranes (e.g., 
phospholipids, cholesterol and proteins) by forming 
inclusion complexes in aqueous solutions to destabilize the 
cell bilayer 7. These structural damages may ultimately lead 
to the disintegration of cell membrane and the toxicity to the 
body 8. 
Carrier systems can increase the residence time of drugs in 
the circulation, can be designed to target drugs to areas in 
need of action and can enhance the bioavailability of many 
sparingly water-soluble drugs 9, 10.  
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 Liposomes as a biodegradable, low toxic and solubilized 
drug delivery system have been widely applied11. 
Hydrophilic drugs are encapsulated within an aqueous 
compartment of liposomes, whereas hydrophobic drugs are 
entrapped within the lipid bilayer. Liposomal formulations 
have shown an ability to enhance the pharmacokinetics and 
pharmacodynamics of encapsulated drugs12 since these 
formulations can induce rapid uptake and long retention by 
the target tissues. Moreover, drugs incorporated in the lipid 
bilayers rather than in the aqueous core of the liposomes are 
prone to more rapid release. Thereby, a hypothesis has been 
proposed to avoid this shortcoming that a poorly water-
soluble drug is first bonded with water soluble carriers and 
then the complexes are encapsulated in the aqueous 
compartment of liposomes. The entrapment of hydrophobic 
drugs in the aqueous core of liposomes as soluble inclusion 
complexes with CDs has been proposed as an interesting 
strategy in 1994, thus obtaining drug in CD in liposome 
(DCL) systems 13. The encapsulation of the drug CD inclusion 
complexes into liposomes combines the advantages offered 
by both CDs and liposomes. CDs increase drug solubility and 
availability, preserve the liposomal structural integrity from 
drug molecules and insert into the lipid bilayer membrane, 
whereas liposomes prevent drug CD complexes dissociation 
due to dilution by the plasma or the facile renal excretion of 
CD molecules. Consequently, this strategy can be useful for a 
better control of the in vivo fate of hydrophobic drugs, 
avoiding the rapid release observed after conventional 
incorporation into the liposome lipid phase14. 
 Poor aqueous solubility and rate of dissolution are the two 
critical factors that affect the formulation and development 
process of drugs and limit their therapeutic application(13). 
The drugs that are poorly soluble and belong to class II or IV 
of biopharmaceutical classification system, represents a 
major challenge 15. Also, it is remarkable that most of the 
cytotoxic anticancer drugs belong to the BCS class IV which 
comprises substances with both low solubility in aqueous 
fluids and low apparent permeability 16. Cyclodextrin (CD) 
complexation based nanocarriers for effective delivery of 
anticancer drugs came into existence 17, 18. This paper 
simultaneously explores the utility of cyclodextrin 
complexation and nanotechnology as unique approach for 
development of drug delivery system.  
2. LIPOSOMES FOR HYDROPHOBIC ANTI-CANCER 
DRUGS FOR CANCER TREATMENT: 
2.1 Liposomes: 
Liposomes are progressed to become a versatile carrier 
system with promising clinical applications several years 
later. Liposomes, are sphere shaped vesicles consisting of 
one or more phospholipid bilayer in which the hydrophobic 
acyl chains are opposite each other within the bilayer while 
the hydrophilic polar ends are placed along the outer rim.  
The advantages of liposomes over the other carrier systems: 
it consists of wide range phospholipids with varying phase 
transition temperature (Tc) is available, providing choice 
between solid or fluid vesicles. Cholesterol can be 
incorporated into the bilayers affecting membrane fluidity 
and stability-important factors for parenteral use. 
Amphiphiles can also be included during preparation to 
produce liposomes with positive or negative surface charge, 
and appropriate ligands such as antibodies19, certain 
glycoproteins neoglycoproteins and glycolipids can be 
attached in order to target liposomes to specific cell surface 
receptors20. All of these properties are applicable to 
liposomes of different sizes, small unilamellar (SUV), large 
unilamellar (LUV) and multilamellar (MLV), each with their 
own intrinsic characteristics and advantages. Anti-tumor 
have been encapsulated either in the aqueous or lipid phases 
of liposomes, and considerable progress in research and 
technology have ensured that liposomes have evolved from 
the theoretical to the practical. 
Liposomal encapsulation technology (LET) is the newest 
delivery technique used by medical investigator21, 22. 
 
Figure 1: Structure of liposomes 
 
Figure 2: Types of Liposomal Systems  
2.2 Properties of Liposomes: 
Two types of liposomes. The bilayer membrane of liposomes 
is mainly composed of phosphatidyl choline (PC) is the 
amphipathic molecule and also known as lecithin in which a 
glycerol bridge links a pair of hydrophobic acyl hydrocarbon 
chains with a hydrophilic polar head group of 
phosphocholine. The length and saturation degree of PC acyl 
chains have an effect on the phase Tm of liposomal 
membrane. Above Tm, rotational isomerization occurs; thus, 
the lipid bilayers become more disordered. It was found that 
M b CD removes cholesterol preferentially from the 
disordered phase in giant unilamellar liposomes when it was 
above Tm 23. In addition, the interactions between CDs and 
liposomes also depend on the lipid composition and the 
Liposome stability after incubation with different CDs was 
studied. Dried rehydrated vesicle (DRV), multilamellar 
vesicle (MLV) and small unilamellar vesicle (SUV) liposomes, 
composed of different lipids, were prepared for calcein 
encapsulation, and the encapsulation stability of calcein was 
tested by incubating with HP b CD, HP g CD or M b CD. It was 
found that M b CD had the most influence on liposome 
stability among these three CDs. It was also demonstrated 
that calcein release rates from vesicles were decreased in the 
order of MLV > DRV > SUV with the same lipid composition. 
The enhanced stability of SUV liposomes could imply that the 
smaller curvature of lipid membrane of SUVs (compared to 
DRV and MLV) did not allow the CD molecules to have 
Jani et al                                                                                                                   Journal of Drug Delivery & Therapeutics. 2019; 9(2-s):598-605 
ISSN: 2250-1177                                                                                  [600]                                                                                 CODEN (USA): JDDTAO 
enough contact angle to interact with the lipid membrane24. 
Moreover, liposomes composed of saturated phospholipids 
(distearoylphosphatidylcholine [DSPC]) were found more 
stable compared to unsaturated egg phosphatidylcholine 
(EPC) liposomes, thus suggesting that phospholipid 
saturation and membrane rigidity have effect on the 
interaction between liposomal lipids and CD molecules. 
3. CYCLODEXTRIN AS A SOLUBILITY ENHANCER: 
Cyclodextrins are the cyclic oligosaccharides of 
glucopyranose units having a lipophilic central cavity and 
hydrophilic outer surface. Their molecules   are large 
comprising a  number of hydrogen acceptors and donors 
which do not permeate lipophilic membranes.The CDs are 
not perfectly cylindrical molecules but are toroidal or cone 
shaped  due to lack of free rotation around the bonds 
connecting the glucopyranose units, 
Depending on their molecular structure and shape, they 
possess a unique ability to act as molecular containers by 
entrapping guest molecules in their internal cavity. During 
drug CD complex formation no covalent bonds are formed or 
broken, and in aqueous solution, the complexes readily 
dissociate and free drug molecules remain in equilibrium 
with the molecules bound within the CD cavity. The parent 
or natural CDs consist of 6, 7 or 8 glucopyranose units and 
are referred to as alpha, beta and gamma CD, respectively. 
CDs containing 9, 10, 11, 12 and 13 glucopyranose units have 
also been reported. Hundreds of modified CDs have been 
prepared and shown to have research applications, but only 
a few of these derivatives, those containing the 
hydroxypropyl (HP), methyl (M) and sulfobutylether (SBE) 
substituents have been commercially used as new 
pharmaceutical excipients. 
The aqueous solubility of many poorly soluble drugs is 
increased by forming inclusion complexes with their apolar 
molecules or functional groups. The resulting complex hides 
most of the hydrophobic functionality in the interior cavity 
of the CD while the hydrophilic hydroxyl groups on the 
external surface remain exposed to the environment. The net 
effect is that a water-soluble CD drug complex is thus 
formed. 
4. DRUG IN CYCLODEXTRIN IN LIPOSOME: 
4.1 Cyclodextrin based Liposomes: 
Liposomes are concentric the vesicles containing an aqueous 
volume that is enclosed by membranous lipid bilayer. They 
entrap hydrophilic drug in the aqueous phase and 
hydrophobic drug in the lipid bilayer. In liposomes, 
cyclodextrin complexation competes with liposomal 
membrane binding, which tempers the potential benefit of 
complexation in prolonging hydrophobic drug retention 25, 26. 
The entrapment of water-soluble cyclodextrin-drug inclusion 
complexes in liposomes leads to accommodation of insoluble 
drugs in the aqueous phase of vesicles, increases the drug to 
lipid ratio, enlarges the range of encapsulation, allows 
targeting of complexes to specific sites27, and reduces 
toxicity. Some of the examples are discussed as under, in the 
year 2006, examined the antitumor effect of PEGylated 
liposomes of DOX complexed with 𝛾-CD, administered 
through intravenous injection in BALB/mice bearing colon 
26 tumor cells. Results reflected retardation in tumor 
growth, increase in drug retention, and improvement in 
survival rate 28. Dhule et al. 2012 evaluated the liposomal 
curcumin’s potential against cancer models of mesenchymal 
(OS) and epithelial origin (breast cancer). The 2-HP-𝛾-
CD/curcumin liposome complex showed promising 
anticancer potential both invitro and in vivo. In another 
study, the antiproliferative and cytotoxic activity of 
anticancer agent LPSF/AC04in cyclodextrin complexed 
liposomes was enhanced29. Cui et al. 2011 developed stable 
PEGylated liposomal vincristine formulation with enhanced 
efficiency using sulfobutylether cyclodextrin as trapping 
agent. This formulation prolonged the circulation half-life 
from 43.6 to 70.0hrs and reduced toxicity 25. Similarly, 
paclitaxel, a first line chemotherapy drug for ovarian cancer 
has also been entrapped in to cyclodextrin to I improve its 
solubility and the whole complex was loaded in liposomes 30.   
Thus, this strategy can be incorporated into several other 
cyclodextrin complexed anticancer drugs into liposomes 
which can ultimately improve their retention inside vesicles. 
4.2 Methods of preparations: 
4.2.1 Two-step methods: 
 There are several methods for preparing DCLs which have 
different impact on the vesicle characteristics. Traditionally, 
the drug CD complexes are first obtained by kneading, spray 
drying, freeze drying, solvent evaporation or saturated 
aqueous solution methods. Then the complexes are further 
encapsulated into liposomal inner aqueous phase by 
different methods to obtain DCLs. 
4.2.2 Thin-film hydration: 
 From different methods of preparing DCLs the most widely 
used method is the thin film hydration method 31,32. The thin 
film is prepared by taking a dried solution of lipids at the 
bottom of a round flask, which is hydrated with drug CD 
complex solution. The extrusion of the above solution is done    
to reduce vesicle sizes. The drug CD complexes can also be 
added into the lipid bilayers of liposomes. The lipid film was 
obtained through evaporating a chloroform solution, which 
contains amphiphilic β CD and phospholipids, and then 
hydrated by buffer solution. It had been demonstrated that 
amphiphilic β CD can be mixed in any proportion with a 
typical mixture of phospholipids and cholesterol to provide 
stable, spherical and unilamellar mixed vesicles 33. 
4.2.3. Dehydration rehydration:  
The dehydration rehydration method, which has been 
demonstrated to allow an efficient entrapment of a wide 
range of drugs, is based on induction of preformed vesicles 
fusion by means of dehydration and controlled rehydration. 
For the preparation of DCLs, 1 palmitoyl 2 oleoyl glycerol 3 
phosphocholine was dissolved in organic solvent and the 
solvent was evaporated to obtain thin lipid film. Then the 
film was rehydrated with water and the lipid suspensions 
were sonicated to reduce vesicle size. The resulting 
suspension was then mixed with 2 ml of 10 mM b CD 
aqueous solution and dried under vacuum at 40C. The 
rehydration was performed by adding 2 ml pH 7.4 PBS and 
incubating the mixture for 20 min at room temperature 
under vortexing34. 3,5 Bis (2-fluoro benzylidene) 4 
piperidone (EF24) is a synthetic analog of curcumin that 
possesses potent anti-proliferative activity against a number 
of cancer cell lines. For EF24 containing DCL preparation, the 
dehydration rehydration method was used. Lipids (DSPC: 
cholesterol: dimyristoyl phosphatidylglycerol = 50:50:5, 
molar ratio) was dissolved in chloroform: methanol (2:1) 
and a thin film of lipids was obtained after evaporation of the 
solvent. Then the film was rehydrated with water, 
maintaining the total lipid concentration to 12 mM. The 
resulting suspension of MLVs was subjected to eight freeze 
thaw cycles. A cycle consisted of snap freezing the 
suspension in liquid nitrogen followed by immediate 
thawing in a 58C water bath. A sterile aqueous solution of 
EF24 HP b CD complex was added to the liposomal 
suspension and the mixture was vortexed for 30 s and 
diluted with pH 7.4 PBS to a lipid concentration of 2 mM. It 
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was found that about 19% of the EF24 HP b CD complex was 
encapsulated inside the liposomes (320.5 ±2.6nm) by this 
technique. With extrusion technique, the size of 177 ± 6.5 nm 
was obtained without any effect on EE 35. 
4.2.4 Active loading: 
 The commercial impact of liposomes is strengthened by the 
invention of several active drug encapsulation methods, 
allowing the encapsulation of several weak base or weak 
acid drugs with very high drug to lipid ratios 36. For the 
preparation of doxorubicin loaded DCL, pH gradient method 
was used. Blank liposomes (lipid composition: 
DSPC/cholesterol/ 1,2distearoyl glycerol 3phospho 
ethanolamine N (carbonyl methoxy polyethylene glycol) 
[DSPE PEG], inner aqueous composition: 300 mM citric acid 
pH 4.0) were prepared by freezing thaw method. The pH of 
the liposome suspension was raised from 4.0 to 7.8 with 1 M 
NaOH. Then doxorubicin γ CD solution was added at the drug 
: lipid weight ratio of 0.2. Doxorubicin loaded CL was also 
prepared by the same technique. The EE of doxorubicin DCL 
and CL were determined to be 91.1 ± 1.1 and 96.4 ± 0.5%, 
respectively37. Gefitinib, an antitumor agent, was 
encapsulated into liposomes by ammonium sulphate 
gradient method. The liposomes were composed of HSPC: 
cholesterol: DSPE PEG (55:45:5, molar ratio). After adding 
0.1M HP b CD in 300 mM (NH4)2SO4 solution, the EE values 
significantly increased from 71.6 ± 1.7% to 85.5 ± 1.2%. CDs 
can form inclusion complexes with drug molecules in inner 
aqueous media of liposomes, hence the increase of drug 
solubility and trans membrane concentration difference 38,39. 
In addition, novel SBE β CD gradient method was proposed 
and SBE β CD anions inside liposomes were found to provide 
the driving force for the loading of drug, because they could 
complex with protonated drugs to improve drug retention 40. 
Active loading is the preferred method for optimizing the 
loading of ionizable drugs in liposomes as measured by drug 
to lipid ratios, but the extremely low aqueous solubilities of 
many hydrophobic drug candidates may limit the external 
driving force, thus slowing liposomal uptake during active 
loading. Therefore, the addition of CDs can improve the 
solubility and the drug loading efficiency of liposomes41. 
4.2.5 One-step method:  
 For the preparation of DCLs, the two step method was 
tedious due to two reasons. First, the preparation of drug CD 
soluble inclusion complexes need a long time (e.g., 48 h). 
Second, the entrapment of inclusion complexes into 
liposomes was usually performed by thin film hydration 
method, limiting industrial production abundantly. The 
spray drying process is considered as a single step, fast 
procedure applied in the formulation and processing of bio 
pharmaceuticals. For the preparation of DCL, the solution for 
spray drying was prepared by suspending lecithin (4.601 g), 
mannitol (0.460 g; presieved), drug (metronidazole [1.026 g] 
or verapamil chloride [7.66 g]) and HP b CD (9 g) in 
chloroform (200 ml). The mixture was sonicated for 8 min 
(bath sonicator) and subjected to spray drying. The dried 
product was hydrated with pH 7.4 PBS stirring for 45 min to 
obtain DCL. It was found that liposomes prepared by the one 
step spray drying method were of regular spherical shape 
regardless of the presence of the drug or CD. No 
morphological difference was observed between empty 
liposomes and liposomes which contain drug, CD or both42. A 
simple and fast one step method was also performed to 
prepare honokiol in HP b CD in liposome43. First, 2.0 mmol 
HP b CD was dissolved in dehydrated alcohol to obtain 2.5% 
(m/v) solution and kept for 0.5 h to let it freely swell. 
Second, 1.0 mmol honokiol was added into the solution and 
the inclusion complex solution was formed by self-
association after stirring for 1 h at room temperature. Third, 
SPC (1.500 mmol), cholesterol (0.4750 mmol), DSPE PEG 
(0.0075 mmol) and vitamin E (0.0175 mmol) were added 
into the inclusion complex solution and the mixture was 
stirred at 60C for the dissolution of lipids. Meanwhile, 2.5% 
(m/v) aqueous phase sucrose solution was heated in a water 
bath at 60C. Fourth, organic phase was slowly injected into 
aqueous phase using a 5 ml syringe under the stirring rate of 
600 rpm and DCL was formed (Figure 2). Then, the sol vent 
was evaporated under vacuum in a rotary evaporator. After 
diluted with 2.5% (m/v) sucrose solution, the suspension 
was freeze dried. The final molar ratio of honokiol: HP b CD: 
lipid was 1:2:2. In the preparation process, the preparation 
of honokiol in HP b CD could be finished in 1 h through 
simple dehydrated alcohol soluble inclusion complex 
method. Meanwhile, the preparation of liposomes was 
performed through simple and fast ethanol injection method. 
Therefore, this whole method of preparing DCL was easy to 
scale up. Although the one step method has such advantages 
as simple, economic and time saving, the form and location 
of drugs in liposomes prepared in this way should be clearly 
demonstrated. 
4.3 Characterization:  
4.3.1 Vesicle size: 
The effect on vesicle size depends on liposome type. The 
encapsulation of drug CD complex resulted in an appreciable 
size increase for MLV, frozen and thawed MLV and large 
unilamellar vesicles (LUV). Celecoxib, a nonsteroidal anti-
inflammatory drug, was encapsulated into MLVs in the form 
of free drug or drug β CD complex. The corresponding vesicle 
sizes were determined to be about 1.32 ± 1.04 µm and in the 
range of 6.52 ± 1.54 10.42 ± 0.44 µm, respectively44. But for 
SUV, no significant size modification was observed in the 
presence of CD, not even when the complex concentration 
was increased. It was reported that the entrapment of drug 
molecules in the lipid bilayer or the encapsulation drug CD 
inclusion complexes in the inner aqueous phase did not 
modify the size of the SUV 45. For blapachone, an antitumor 
agent, the drug loaded CL in the suspension dosage forms 
presented vesicle sizes of 104 ± 2.33 nm, whereas the DCL 
under the same circumstance presented vesicle sizes of 112 
± 1.49 nm, respectively 32. The pore size of the membrane 
determined the particle size of the liposomes, on which the 
presence of CD can have little effect. Sometimes the 
enhancement of the vesicle size during storage is found, 
which means that the stability of DCL is probably 
unsatisfactory. A hypothesis of the DCL particle size 
enhancement is that CDs could replace the drug molecules 
for the lipid components, especially cholesterol, from 
liposomes by forming inclusion complex with them. Thus, it 
could destabilize the bilayers of DCLs. 
4.3.2 Entrapment efficiency: 
The amount of hydrophobic drug incorporated into the CL 
bilayer is often limited in terms of drug to lipid ratio. 
Entrapping inclusion complexes in liposomes has been 
proposed to increase the EE and stability of liposomes 
compared with CLs. For EF24, an analog of curcumin, the 
conventional thin film hydration method provided only 0.4% 
EE which increased to 1% when a reverse phase evaporation 
method was used for CL preparation. It was obvious that 
lipid compartment of the liposomes was not able to host 
EF24, and the aqueous solubility of EF24 was not large 
enough for its accommodation inside the aqueous core. EF24 
solubility in water increased remarkably from 1.64 to 13.76 
mg/ml after complexation with HP β CD. And the complexes 
were further encapsulated into liposomes. The EE of EF24 
DCL was determined to be 19.7%. The enhancement in EE 
could be attributed to the encapsulation of more soluble 
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EF24 complexes into the aqueous liposomal core which 
provided a relatively larger volume than lipid bilayers. The 
type of CDs could affect the EE values of DCLs. For 
ketoprofen containing DCLs, the complex with HP β CD,in 
virtue of its greater stability than the complex with β CD, 
allowed higher EE and gave rise to more stable MLV systems 
46. As for SUV, HP β CD also seemed to be superior to β CD in 
consideration of drug loading capacity. The drug: lipid ratios 
were determined as 0.321, 0.102 and 0.778 for prednisolone, 
prednisolone: β CD and prednisolone: HP β CD containing 
liposomes composed of EPC and cholesterol (1:1, molar 
ratio) 47. For DCL, the EE also depended on both the liposome 
preparation method and the complex concentration in the 
aqueous phase and was in the order of MLV > LUV > SUV. 
SUV vesicles showed the lowest EE value compared with the 
other types of DCLs. The reduced volume of the aqueous 
compartment, with respect to the other formulations, due to 
the smaller dimensions of these unilamellar vesicles can be 
considered as the main factor responsible for this result48. In 
addition, EE value increased with the increase of the HP β CD 
complex concentration up to 10 mM. Moreover, it was not 
possible to use higher complex concentrations, due to the 
destabilizing effect of CDs toward the liposomal 
membrane48. 
4.3.3 Release profile Encapsulation of drug:  
CD complexes into inner aqueous phase of liposomes could 
result in a modulation of the in vitro kinetics of release of 
drug molecules. In most cases, 
DCLs presented a more prolonged release profiles compared 
to CLs. The slow release pattern of the DCLs may be 
attributed to the fact that there are more barriers to the 
diffusion of drug from the DCLs (44). The release profiles of 
three different usnic acid loaded formulations (inclusion 
complex, CL, DCL) were compared. Usnic acid in inclusion 
complex released practically 50% of usnic acid at 3 h, 
corresponding to the initial burst effect, followed by a linear 
release of 80% at 11 h, reaching 99.1% in 30 h. The release 
of usnic acid from CL reached 30% within 7 h and 55% in 24 
h, achieving 70% in 72 h, whereas the release of usnic acid 
from DCL was significantly slower (32.5% at 24 h) than from 
CL (50% at 20.5 h and 65% at 33 h) . For liposomes 
containing amphotericin B, amphotericin B HP β CD complex 
and amphotericin B SBE β CD complex, 65.1 ± 8.5, 12.2 ± 3.6 
and 11.8 ± 3.4 % drug molecules were found released from 
vesicles at 60 min in pH7.4 PBS, respectively 49. As for DCL, 
two routes may account for the drug release. One is that drug 
CD inclusion complexes are transported from inner aqueous 
phase to lipid bilayers, and then the whole inclusion 
complexes are released50. The other way is the release of free 
drug, which is in equilibrium with the inclusion complexes in 
inner aqueous phase of DCLs. The release rate is affected by 
a constant of inclusion complexes. Whether the release 
process follows one route or the other, the lipid bilayer 
barrier should be overcome at first49. Since HP β CD 
entrapped in the aqueous compartment of liposomes was 
found to be membrane impermeable51, the latter way might 
be the main drug release route for DCL containing drug HP β 
CD complexes. 
4.3.4 Pharmacokinetics:  
If drug CD complexes are injected directly, rapid dissociation 
of the complexes takes place because of either dilution or dis 
placement of the included drug by other blood components. 
The released drug is then distributed and metabolized as 
free drug, while the CD moiety is excreted through the 
kidneys. Therefore, the improvement of pharmacokinetics in 
vivo following complexation with CDs might be limited. In 
addition, after intravenous administration of naked drug CD 
complexes, interaction of CD molecules with cholesterol of 
red blood cells may lead to drug displacement from the 
complexes and subsequent haematological toxicity. For 
curcuminoid 4 [3,5 bis (2chlorobenzylidene 4 oxo piperidine 
1yl) 4 oxo 2butenoic acid], a novel antitumor agent, if 
intravenously injected in the form of HP β CD inclusion 
complex, renal clearance of complex accounting for > 50% 
elimination within the first 10 min after administration was 
observed. Therefore, DCL was selected for the drug because 
liposomes were eliminated through a relatively slower 
reticuloendothelial route which can be further delayed by 
altering the liposomal composition 52. DSPC liposomes 
containing entrapped complexes of 14C labelled HP β CD 
with 3H labelled drugs were prepared. Intravenous injection 
of free complexes into rats led to their rapid clearance from 
the circulation with up to 94% of HP β CD recovered in 24 h 
urine together with lesser and variable amounts of drug (up 
to 46% of the dose). After injection of DCLs, only 6 13% of 
HP β CD and a moderate proportion of drugs (up to 26% of 
the dose) were recovered in 24 h urine. Most of the HP β CD 
was recovered in the liver (up to 83%) and spleen (up to 
13% of the dose) 30 min after injection, together with a 
variable proportion of drugs. Therefore, compared to drug 
CD complexes, administration of DCLs could serve as a better 
means to control the action of a wide range of therapeutic 
agents. Encapsulation into DCLs can lead to significantly 
improved pharmacokinetic properties of hydrophobic drugs. 
The results of plasma pharmacokinetics revealed that free 
honokiol was quickly removed from the circulating system 
after intravenous injection. However, honokiol in HP β CD in 
liposome significantly retarded the elimination and 
prolonged the residence time in circulating system. 
Indomethacin DCLs were obtained by encapsulating 
indomethacin b CD or HP β CD inclusion complexes into 
liposomes. After intravenous injection, for indomethacin CL 
(encapsulated into lipid bilayers), T1/2b and AUC0 -- ¥ 
values were determined to be 75.4 ± 13.6 min and 3904 ± 
23.4 µg/ml min, respectively. For b CD DCL, the 
corresponding values were determined to be 106.8 ± 16.8 
min and 5808 ± 50.9 µg/ml min, respectively. And for HP b 
CD DCL, the corresponding values were determined to be 
122.7 ± 63.1 min and 6290 ± 150.7 µg/ml min, 
respectively53. Considering that encapsulation of drug CD 
complexes into liposomes results in a slow release profile in 
vitro, therefore, the systematic circulation time of the drug is 
prolonged54. 
4.3.5 Antitumor activity:  
LPSF/AC04, (5Z) [5acridin 9ylmethylene 3 (4 methyl benzyl) 
thiazolidine 2,4dione], is an acridine based derivative. 
Evaluated with human breast cancer T47D cells in vitro, the 
IC50 values of 82.57 ± 9.26 and 65.06 ± 5.95 µM were found 
for free LPSF/AC04 and LPSF/AC04 CL (encapsulated into 
lipid bilayers), respectively. On the other hand, IC50 values 
of 35.00 ± 13.6 and 32.00 ± 14.8 µM were found for the 
liposomal formulations containing inclusion complexes 
(LPSF/AC04 HP β CD and LPSF/AC04 HP g CD), respectively. 
These results clearly demonstrated that the incorporation of 
LPSF/AC04 CD inclusion complexes into liposomes increased 
the cytotoxicity activity by twofold over LPSF/AC04 loaded 
liposomes 45. It was concluded that DCL strategy was an 
alternative means of overcoming drug’s poor solubility, as 
well as probably improving drug penetration into the cells 
and enhancing drug antiproliferative activity. Antitumor 
efficacy against human lung adenocarcinoma NCI H441 and 
prostate cancer PC 3 cell lines in vitro was investigated and 
compared between EF24 loaded DCL and free drug. In 
general, it was observed that EF24 DCL exceeded the 
antiproliferative activity to plain EF24 (p < 0.05) . Following 
intravenous injection to the tumor bearing mice, the AUC 
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value of DOX in solid tumors up to 72 h in the PEGylated DCL 
system was ~ 2.3 times higher than that of the PEGylated CL 
system. The AUC values of DOX in plasma were determined 
to be 1338 ± 97 and 2090 ± 54 µg h/ml for DOX CL and DCL, 
respectively37. Enhanced AUC levels of drug in plasma and 
solid tumors after intravenous injection of DCL or CL could 
be attributed to the slow release profiles of the PEGylated 
DCLs. Consequently, the improved antitumor activity in vivo 
of DCLs was expected compared to free drug or drug loaded 
CLs. Nevertheless, the antitumor activity of DCLs in vivo 
should be intensively investigated. In addition, to increase 
efficacy of chemotherapeutic drugs, toxicity of the drugs 
could also be reduced through DCL. Following intravenous 
administration of trans dehydrocrotonin (T DCTN) 
suspension, the microsteatosis and cell degeneration were 
more pronounced in the hepatocytes of mice55. There were 
few changes in animal livers treated with T DCTN loaded CL 
and even fewer of those treated with DCL. The decrease in 
the hepatotoxicity of mice treated with CL and DCL might be 
due to a lower concentration of drug in the liver. 
4.3.6 Transdermal absorption:  
The clinical application of liposomes can carry a risk of acute 
immune toxicity manifested in hypersensitivity reactions 
that do not involve IgE but arises as a consequence of 
activation of the complement system 56. Therefore, although 
no immune toxicity is reported until now, more attention 
should be paid to the similar risk of the application of DCLs. 
CLs have been proved having little value as carriers for 
transdermal drug delivery, because they are generally 
accumulated in the upper layers of the stratum corneum (SC) 
with minimal permeation to deeper tissues or the systemic 
circulation 57. With the incorporation of edge activator in the 
lipid bilayer structure, a new type of liposomes, elastic 
liposomes, was first introduced by Cevc and Blume in 1992 
58. Due to the deformability, elastic liposomes are claimed to 
be able to squeeze through channels one tenth the diameter 
of the vesicles 59, allowing them to penetrate across SC by the 
inter cellular route. Elastic liposomes have been widely 
applied for the transdermal drug delivery 60. Edge activator 
is usually a kind of surfactant, which destabilizes lipid 
bilayer of the elastic liposomes and increases elasticity of the 
bilayer simultaneously. Among edge activators, sodium 
cholate, sodium deoxycholate, Span 80, Tween 80 and Tween 
20 were commonly used. In 2008, elastic DCLs were first 
reported by Jain et al. for the transdermal delivery of 
meloxicam, an anti-inflammatory agent. The results of in 
vitro skin permeation studies revealed that elastic DCL 
enhanced skin permeability compared to elastic CL and free 
drug. The maximum flux obtained from meloxicam loaded 
elastic DCL was substantially 9.1 times higher than that of 
plain drug and nearly 1.4 times higher than elastic CL. 
Theoretically; the entrapment of drug CD complexes into 
elastic liposomes will increase the advantage of both of them. 
On one hand, CD plays a role as a solubilizer agent, a 
chemical protector and sometimes a permeation enhancer 61. 
On the other hand, the elastic liposome seems to be able to 
penetrate into the intact skin when it is administered under 
nonocclusive conditions. Results of skin permeation and 
deposition study showed that encapsulation of isotretinoin 
HP β CD complex into elastic liposomes significantly 
increased the skin deposition. At the end of skin permeation 
experiments in vitro (24 h), 1.2, 3.0, 16.1 and 26.2% drug 
deposition were found in skin for isotretinoin solution, HP β 
CD complex, elastic CL and elastic DCL, respectively. Besides 
good reservoir effect, the flux across skin in vitro was also 
found to be enhanced by elastic DCL62. The deformability of 
liposomal vesicles was not affected by the encapsulation of 
drug CD complexes 63. Moreover, the vesicle characteristics 
could be improved by DCL strategy. The percentage of β 
methasone released was 20.9 ± 1.6% for classical liposomes 
encapsulating β methasone HP γ CD inclusion complexes 
versus 44.7 ± 3.1% for elastic ones. The percentage of b 
methasone released was 76.5 ± 2.1% for classical liposomes 
containing b methasone in the lipid bilayer and 82.7 ± 4.1% 
for elastic ones 30. Based on these results, it is proved that 
the strategy of DCL improves the retention of β methasone 
inside the liposome cavity, which might account for the good 
reservoir effect of elastic DCLs. However, for some drugs, 
encapsulation into elastic DCL has little effect on the vesicle 
properties compared to elastic CL. There is no statistically 
significant difference between the physicochemical 
parameters of elastic liposomes with quercetin and 
resveratrol entrapped or encapsulated as CD inclusion 
complexes64. To obtain stable elastic DCL, CDs should have a 
higher affinity for drug molecules than for membrane lipids 
activators.Thus the entrapment of highly concentrated drug 
CD inclusion complex into liposomes will has no or only 
minimal interaction with lipid components of the liposomal 
membrane. Therefore, if CD has lower affinity for the drug 
than the lipids or edge activators, the vesicle proper ties 
could not be improved by elastic DCL strategy. Subsequently, 
the improved skin permeation behaviour could not be 
expected. 
CONCLUSIONS 
It has been observed through this review the liposomes and 
the cyclodextrins as drug delivery systems have contrasting 
characteristics, interaction with biological environment, 
mode of dug delivery and entrapment. However, these two 
systems are improved over the years.  Liposomes are 
designed with predetermining optimal drugRelease and 
diverse circulatory residence times, similarly hydrophilicity 
increased by derivatisation in Cyclodextrins and it became 
less toxic. Therefore, Cyclodextrins bioavailability and 
therapeutic efficiencies are improved. There are certain 
disadvantages of each system but it can be cured by the 
entrapping cyclodextrin complexes into liposomes to 
produce a single system and preliminary resultsare 
promising.Work needs to be done to optimize the system in 
order to understand the factorsinvolved in drug 
displacement and to establish conditionsof entrapment 
whereby this can be reduced.The stability and entrapment 
behavior of additionaldrug/cyclodextrin complexes also 
needsinvestigation. 
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